Drug intelligence / Profile preview

JNJ-64300545

Development stage: Discontinued
Lead developer: OMJ Pharmaceuticals
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

JNJ-64300545 is an investigational Janssen-associated **hepatitis B virus therapeutic DNA-vaccine program** reportedly developed in collaboration with Ichor Medical Systems. Public pipeline-derived material characterizes it as targeting hepatitis B virus antigens to induce HBV-specific immune responses for chronic hepatitis B. However, the exact identifier is poorly corroborated and may have been conflated with the distinct, well-documented Ichor/Janssen DNA vaccine **JNJ-64300535**; therefore, details on its construct, antigen composition, delivery method, clinical studies, and definitive development history remain unconfirmed.

Targets

HBV antigens (Hepatitis B virus antigens)

Beyond the preview

Go deeper on JNJ-64300545.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-64300545.

Explore the full profile